Page 7 - ஹீமாட்டாலஜி சிகிச்சையகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஹீமாட்டாலஜி சிகிச்சையகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஹீமாட்டாலஜி சிகிச்சையகம் Today - Breaking & Trending Today

Researchers evaluate frequency of SARS-CoV-2 in hematology/oncology settings

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. ....

Andrewm Evens , Emily Henderson , Lymphoma Program At Rutgers Cancer Institute , Rutgers Robert Wood Johnson Medical School , Robert Wood Johnson University Hospital , Rutgers Cancer Institute Of New Jersey , Lymphoma Program , National Cancer Comprehensive Center , Rwjbarnabas Health , Clinical Services , Rutgers Cancer Institute , New Jersey , Associate Director , Rutgers Cancer , Rutgers Robert Wood Johnson Medical , Bone Marrow , Sars Cov 2 , T Cell , எமிலி ஹென்டர்சன் , லிம்போமா ப்ரோக்ர்யாம் இல் ரட்ஜர்ஸ் புற்றுநோய் நிறுவனம் , ரட்ஜர்ஸ் ராபர்ட் மரம் ஜான்சன் மருத்துவ பள்ளி , ராபர்ட் மரம் ஜான்சன் பல்கலைக்கழகம் மருத்துவமனை , ரட்ஜர்ஸ் புற்றுநோய் நிறுவனம் ஆஃப் புதியது ஜெர்சி , லிம்போமா ப்ரோக்ர்யாம் , தேசிய புற்றுநோய் விரிவான மையம் , மருத்துவ சேவைகள் ,

Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab


Date Time
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma. The study evaluates the efficacy and safety of elranatamab, administered subcutaneously, in patients with disease that is refractory to at least one agent in each of three major classes of medications approved for multiple myeloma. The study’s estimated primary completion date is June 2022. ....

United States , Alexanderm Lesokhin , Susie Novis Durie , Chris Boshoff , Pfizer Inc , International Myeloma Foundation , Drug Administration , Pfizer Global Product Development , Virtual American Society Of Hematology , Memorial Sloan Kettering Cancer Center , Fast Track Designation , Fast Track , Chief Development Officer , Pfizer Global Product , Virtual American Society , Annual Meeting , Memorial Sloan Kettering Cancer , International Myeloma , Immune Response , ஒன்றுபட்டது மாநிலங்களில் , ஃபைசர் இன்க் , சர்வதேச மைலோமா அடித்தளம் , ஃபைசர் உலகளாவிய ப்ராடக்ட் வளர்ச்சி , மெய்நிகர் அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , வேகமாக டிராக் பதவி ,

Dana-Farber Medical Oncology Chair receives Sjöberg Prize for cancer research


Date Time
Dana-Farber Medical Oncology Chair receives Sjöberg Prize for cancer research
Benjamin Ebert, MD, PhD, Chair of Medical Oncology at Dana-Farber Cancer Institute, George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and Institute Member of Broad Institute of Harvard and MIT, has been awarded the Sjöberg Prize, an annual international prize in cancer research. The prize was awarded for Dr. Ebert’s discovery of the mode of action of lenalidomide in the treatment of hematological disorders.
This is the fifth time that the Sjöberg Prize will be awarded. The Royal Swedish Academy of Sciences selects the laureates and the Sjöberg Foundation provides the financing. The prize amounts to one million dollars, of which $100,000 is the prize sum and $900,000 is funding for future research. ....

United States , Dana Farber Cancer Institute , Williams College , Georgep Canellos , Peter Ratcliffe , Benjamin Ebert , International Society Of Experimental Hematopoiesis , Investigator Of The Howard Hughes Medical Institute , American Society For Clinical Investigation , Harvard Medical School , Institute Member Of Broad Harvard , Royal Swedish Academy Of Sciences , National Academy Of Medicine , American Society Of Hematology , Prize Committee , Oncology At Dana Farber Cancer Institute , Oxford University , Association Of American Physicians , Medical Oncology , Institute Member , Broad Institute , Royal Swedish Academy , Howard Hughes Medical Institute , National Academy , American Society , Clinical Investigation ,